Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity
Open Access
- 15 January 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (2) , 601-604
- https://doi.org/10.1158/0008-5472.can-05-2967
Abstract
This review shows how tumor antigen cross-presentation is affected by the major therapeutic modalities including chemotherapy, radiotherapy, and surgery. We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment. (Cancer Res 2006; 66(2): 601-4)Keywords
This publication has 24 references indexed in Scilit:
- Escort service for cross-primingNature Immunology, 2005
- UNDERSTANDING PRESENTATION OF VIRAL ANTIGENS TO CD8+T CELLS IN VIVO: The Key to Rational Vaccine DesignAnnual Review of Immunology, 2005
- Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer PatientsThe Journal of Experimental Medicine, 2004
- Antigen Bias in T Cell Cross-PrimingScience, 2004
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003
- Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-AntigensThe Journal of Experimental Medicine, 2002
- How Many Mutations in a Cancer?The American Journal of Pathology, 2002
- The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic CellsThe Journal of Experimental Medicine, 2000
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Cell-mediated cytotoxicity to SV40-specific tumour-associated antigensNature, 1976